Novo Nordisk and Amylin - Bydureon Approval in the US - A Positive signal for the class
The approval of Bydureon in the US for the treatment of Type 2 diabetes, is important for the entire GLP-1 class and is a positive signal for the one’s in the pipeline. There are about 34 GLP-1 pipeline candidates and are being designed for significant enhancement over current marketed GLP-1’s. We forecast $3billion in peak sales for the Amylin’s GLP-1 franchise (Byetta, Bydureon and once monthly exenatide suspension). Bydureon is currently available in custom dosing kit, but will be soon replaced by a pen version (YE 2012/early 2013). The once monthly exenatide suspension (QM/QW) in a pen device (not require reconstitution), currently in PhIII is expected to reach the market beyond 2013, and will help Amylin further build its dominance in the GLP-1 space.
COMPANIES MENTIONED
NOVO NORDISK, AMYLIN
NOVO NORDISK, AMYLIN
